PROBLEMS
Although the efficacy of aphasia therapy has been demonstrated, the very fact that this demonstration continues to have detractors shows that the treatment of aphasia, despite its effectiveness, remains unsatisfactory. Why is this the case? These problems devolve both from society's conception of stroke and stroke therapy and from our limited understanding of the pathophysiology of the late stages of stroke. Although the societo-political views of stroke and stroke treatment make contemporary treatment difficult, we will focus here on issues for the future of such treatment. It is the premise of this essay that the therapeutic options for subacute and chronic stroke are too limited, that the goals of such therapy are by far too modest, and that aphasia therapy represents a particularly difficult challenge because of the inherent complexity of language and of the brain's mechanisms for using it.
Contemporary society views stroke solely as an acute disease, like myocardial infarction ("heart attack"), rather than as a chronic disease, like diabetes mellitus ("sugar"). Whereas it is readily acknowledged that treatment for diabetes must be lifelong, treatment for stroke must be completed within a few days to a few weeks. Certainly stroke has an acute, time-critical, emergency aspect (i.e., "brain attack"). However, recognizing that stroke also requires long-term ongoing treatment, like diabetes, would dramatically alter therapy. Whereas society views acute stroke treatment in biological and chemical terms, it views treatment of subacute and chronic stroke (e.g., aphasia) as an educational issue.
Very little is known about the pathophysiology of the post-acute stages of stroke. For example, while the manifestations of aphasia change in certain ways over the course of recovery, based on the original manifestations, the age of the patient, mode of therapy, and other factors (Holland, Greenhouse, Fromm, & Swindell, 1989) In what ways are the therapeutic options for aphasia limited? The main limitation is the constraint that therapy not be directed at the damaged structure itself, but rather at the external manifestations of this structure. Thus, if a patient has a Broca Aphasia and has damage to the left frontal lobe, we try to teach him to make full sentences (education) rather than trying to fix the left frontal lobe (biology). Earlier in this century, if this same patient had a post-stroke depression, we would teach him to understand the context, to view the positive side of things, to perceive more options, and to "talk it out". This same patient today would have repletion of the presumed serotonin deficit in the damaged region, with far greater efficacy and lower cost.
How are therapeutic goals for aphasia treatment too modest? The answer to this is easily predicted: The best of modern aphasia treatments try to make small restorative or compensatory changes in language behavior, without ever aspiring actually to cure aphasia. The main reason that we limit our aspirations in this way is that it has been inconceivable to make more than very modest gains in linguistic or communicative performance after large left hemispheric infarcts. So, while aphasia treatment helps, it doesn't do enough, and its aspirations are generally too modest for patients and families, and the rapidity and extent of gains from existing approaches keep patients frustrated and disappointed.
Why is aphasia therapy a particularly difficult challenge for the coming century? Language is the most complex of human cognitive functions, and neither the nature of human language itself nor the brain mechanisms for producing or receiving it are understood. Although there appear to be commonalties among natural languages, and general principles that hold for language (Chomsky, 1965) , linguistic observations have had little if any impact on the understanding of language disorders (controversial) or the human brain (not controversial). By their very nature, language functions have qualitatively different brain representations than sensorimotor functions. Whereas language use involves a large amount of the cerebral cortex, it does not map straightforwardly to the environment, as do certain aspects of sensorimotor function (e.g., sensory receptive fields, motor somatotopy). As a result, much more is known about the neural circuits underlying sensory and motor function than language function, and thus the therapeutic challenge in aphasia is magnified. In the next section, we discuss biological therapies for chronic stroke, and although they may have their first trials in motor recovery, they will ultimately be applicable for language recovery, and will present formidable challenges.
SOLUTIONS
So what does the future hold for aphasia therapy? It is our view that aphasia therapy in the new century will include three complementary factors: (a) transplantation of neural stem cells (Snyder & Macklis, 1995) , embryonal carcinoma cells (Borlongan, Tajima, Trojanowski, Lee, & Sanberg, 1998b) , or neurons (Trojanowski, Kleppner, Hartley, Miyazono, Fraser, Kesari, et al., 1997) into the area of infarction; (b) supplementation of the local environment with adjunctive pharmacological agents, including transmitter and modulator agonists and antagonists (Feeney, Gonzalez, & Law, 1982) , neurotrophins (Wu & Pardridge, 1999) , other chemical modulators, some of which might even been delivered by gene transfer (Yang, Clifton, & Hayes, 1997) ; (c) functional therapy aimed at retraining the new circuitry and integrating it with preserved existing tissue (Holland & Forbes, 1993) . A fourth possibility is that integrated circuit chips could be directly implanted and integrated with the brain. In this essay, we will focus on the combination of the first three.
Tissue transplantation is becoming viable for stroke, even at the present. In animal models, transplantation has been undertaken using several different cell types for ischemic injury at several different stages. The most prominent of these efforts, using human neurons derived from a clonal embryonal carcinoma cell line (Trojanowski, et al., 1997) , have had some success in a rodent model (more than did fetal rat striatal cells) (Borlongan, Saporta, Poulos, Othberg, & Sanberg, 1998a) , and has recently been attempted in humans (1998). These studies have generally assessed motor behavioral recovery, but have used a middle cerebral artery occlusion model, and thus have addressed (to the extent possible) cerebral cortical injury as is the case in a person with aphasia.
Pharmacotherapy has not yet fulfilled its promise, despite many decades of effort (Linn, 1947; Small, 1994b) . Although dextro-amphetamine and other agents that affect catecholamine systems appear to aid motor stroke recovery in animal models (Feeney, et al., 1982; Hovda & Feeney, 1984) , and some trials in motor recovery (Clark & Mankikar, 1979; Crisostomo, Duncan, Propst, Dawson, & Davis, 1988) and aphasia report success (Walker-Batson, Unwin, Curtis, Allen, Wood, Smith, et al., 1992), other studies have not found clear benefit from such pharmacotherapy (McNeil, Doyle, Spencer, Goda, Flores, & Small, 1997; Small, 1994b) . Although there remains some controversy about the role of dextro-amphetamine in promoting stroke recovery, and there is presently an ongoing clinical trial to assess this issue (Blakeslee, 1999) , there is general agreement on one important facet of drug therapy: Catecholaminergic agents such as dextro-amphetamine do not help stroke recovery in the absence of behavioral therapy or practice. Successful trials of dextroamphetamine for motor stroke, both in animal models (Feeney, et al., 1982) and humans (Walker-Batson, Smith, Curtis, Unwin, & Greenlee, 1995) , have used drug therapy as an adjunct to behavioral practice (e.g., a spinning wheel for a rodent) or to standard physical therapy.
For aphasia recovery, as with motor recovery, the nature of the relationship between drug therapy and functional interventions remains to be determined. Although this is equally true with respect to neuronal transplantation, the role of functional retraining has not been mentioned in this context. The interaction between behavioral and biological interventions is extremely complex, particularly so for language, yet it is the elucidation of this relationship that is fundamental to the future of aphasia therapy.
Although different aphasia therapies are usually considered to be either effective or ineffective in particular settings, they have not generally been thought of as having a potential for harm. Thus, it is perfectly reasonable to try one approach, and if it doesn't work, to try another, without ever facing a risk of detriment to the patient (other than prolonging recovery). This may not be correct. If aphasia treatments have the potential to change the brain (Small, Flores, & Noll, 1998) , then they have the potential to change it both for better or for worse. This radical notion has been studied to a limited degree in the motor system (Taub, Miller, Novack, Cook, Fleming, Nepomuceno, et al., 1993) , with the notion that some patients develop a "learned non-use" of a paretic extremity, due to behavioral habits that minimize the use of the extremity, and concomitantly alter the brain to exacerbate recovery.
The argument presented here is that aphasia therapy is at a crossroads. Very soon, it will be possible to intervene biologically to replace damaged brain tissue and/or neural transmitter and modulators, and to provide the potential for significant functional recovery. However, we must be ready to face the behavioral challenge: These neural circuits, damaged and replaced, will need to be integrated not only into a biological organism, but also a behavioral organism. Further, proper integration into the biological system may require proper behavioral intervention. Given what we know about artificial neural networks in language and aphasia (Harris & Small, 1998; Small, 1994a) , it seems highly likely that transplanted and/or pharmacologically altered natural neural networks will require significant attention to training. Much data exists from the world of modeling to suggest that providing the wrong training to a network can lead both to failures to learn (Elman, 1993) and/or to unlearning of previous material (McCloskey & Cohen, 1989) .
Aphasia therapy after biological intervention may thus need to meet new standards, not ones of effectiveness and ineffectiveness, but standards of benefit versus harm. At the present time, a number of different therapeutic methods exist (Holland & Forbes, 1993; Small, 1998) , ranging from "general stimulation" (Shuell, Jenkins, & Jimenez-Pabon, 1964 ) to symp-tombased approaches (Helm-Estabrooks & Albert, 1991) to theoretically motivated methods from psychology (Schwartz, Saffran, Fink, Myers, & Martine, 1994) , linguistics (Thompson, Shapiro, Ballard, Jacobs, Schneider, & Tait, 1997) , and neural networks (McNeil, Doyle, Spencer, Goda, Flores, & Small, 1996) , to methods addressing functional communication without necessarily focussing on language per se (Kagan & Gailey, 1993; Wilcox & Davis, 1979) . Although the efficacy of aphasia treat-ment itself has been demonstrated (e.g., (Robey, 1994; Wertz, Weiss, Aten, Brookshire, Garcia-Bunuel, Holland, et al., 1986) ), treatment success is by comparison with no treatment. In this new era, different aphasia treatments will have to be evaluated in terms of both benefit and detriment to biological and behavioral recovery of brain circuits for language (and concomitant functional recovery).
CONCLUSIONS
The premises of this essay were that options for stroke therapy are too limited, the goals far too modest, and that aphasia therapy is particularly problematical. The solution proposed here is to use novel biological therapies, including stem cell infusion, neuronal transplantation, and pharmacotherapy, to make the brain amenable to more dramatic change in function. However, this will put new responsibilities on therapists, requiring a shift from "effective therapy" (by comparison with no therapy) to "beneficial therapies" to achieve certain particular biological and behavioral goals (by comparison with harmful therapies). This will be particularly acute for aphasia treatment because of the complexity of human language, poor understanding of its biology, and limited knowledge about the particular effects of particular therapies. The new millennium thus presents both tremendous anticipation and tremendous challenges for aphasia treatment. With careful and successful research, the methodology of our clinical approach may be fundamentally changed for the better.
